Vaccines and vaccination: the way out of the coronavirus pandemic

9 DECEMBER 2020

THE EUROPEAN COMMISSION HAS BEEN WORKING SINCE JUNE TO SECURE THE MOST PROMISING COVID-19 FUTURE VACCINES.
Now that we have one of the most comprehensive vaccine portfolios in the world, we need to get ready for rapidly granting marketing authorisation to those vaccines. At the same time, the vaccines will still undergo rigorous scientific assessment to ensure they are effective and safe.

MEMBER STATES:
PREPARATION OF VACCINATION AND DEPLOYMENT OF VACCINES

MEMBER STATES SHOULD
- Identify the priority groups for vaccination
- Prepare the infrastructure and logistics of vaccination campaigns at a large scale
- Have the necessary equipment
- Train health workers
- Communicate and inform about the vaccines to address citizens’ concerns and build trust

EUROPEAN MEDICINES AGENCY: EVALUATION OF VACCINE CANDIDATES
- Evaluation starts as soon as the vaccine producers request a marketing authorisation.
- To speed up the process, the Agency has already started analysing certain data about the vaccine

EUROPEAN MEDICINES AGENCY: RECOMMENDATION REGARDING THE VACCINE CANDIDATES
- If it finds that the vaccine is safe and effective, the Agency recommends that a marketing authorisation is granted

EUROPEAN COMMISSION: AUTHORISATION OF THE VACCINE
- The Commission grants market authorisation of the vaccine, based on the recommendation from the European Medicines Agency

MEMBER STATES: PURCHASE VACCINES
- Member States order vaccines from the vaccine producer, in line with the population-based distribution key

MEMBER STATES: START VACCINATION BASED ON THEIR NATIONAL STRATEGIES

MEMBER STATES AND EUROPEAN COMMISSION: ONGOING SAFETY MONITORING
- Once a vaccine is on the market, its safety is constantly monitored
- If an anomaly is reported, there is immediate follow up